Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial

A randomized double-blind clinical trial was performed to test the safety and efficacy of a low-molecular-weight heparin, tinzaparin (Innohep), for the management of acute painful vasoocclusive crisis characteristic of sickle cell anemia (SCA). We studied 253 patients with acute painful crisis but w...

Full description

Saved in:

Bibliographic Details
Published in:	Thrombosis and haemostasis Vol. 98; no. 2; p. 392
Main Authors:	Qari, Mohamad Hasan, Aljaouni, Soad Khalil, Alardawi, Mohamad Salleh, Fatani, Huda, Alsayes, Fatin Mohamad, Zografos, Panagiotis, Alsaigh, Mohamad, Alalfi, Adnan, Alamin, Mohamad, Gadi, Abdulilah, Mousa, Shaker A
Format:	Journal Article
Language:	English
Published:	Germany 01-08-2007
Subjects:	Adolescent Adult Anemia, Sickle Cell - complications Anemia, Sickle Cell - drug therapy Antisickling Agents - therapeutic use Double-Blind Method Female Fibrinolytic Agents - therapeutic use Hemorrhage - chemically induced Heparin, Low-Molecular-Weight - administration & dosage Heparin, Low-Molecular-Weight - adverse effects Hospitalization Humans Male Pain - prevention & control Pain Measurement Vascular Diseases - drug therapy Vascular Diseases - etiology Vascular Diseases - prevention & control
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A randomized double-blind clinical trial was performed to test the safety and efficacy of a low-molecular-weight heparin, tinzaparin (Innohep), for the management of acute painful vasoocclusive crisis characteristic of sickle cell anemia (SCA). We studied 253 patients with acute painful crisis but with no other complications of SCA, randomized to treatment or control groups. In the treatment group, 127 patients received tinzaparin at 175 IU/kg, subcutaneous once daily, along with supportive care including morphine analgesia; in the control group, 126 patients received placebo and the same supportive care. The maximal experimental treatment period was seven days. Analysis revealed a statistically significant reduction in number of days with the severest pain score, overall duration of painful crisis, and duration of hospitalization (p < 0.05 for each comparison of tinzaparin vs. placebo). The decline in pain intensity was sharper for tinzaparin-treated patients, and complications consisted of two minor bleeding events that were reported and treated by cessation of tinzaparin. This investigation demonstrated that tinzaparin, administered at its approved treatment regimen, reduced the severity and duration of acute crisis of SCA.
ISSN:	0340-6245
DOI:	10.1160/TH06-12-0718